Prudential Financial Inc. decreased its position in Genomic Health, Inc. (NASDAQ:GHDX) by 6.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 184,070 shares of the medical research company’s stock after selling 11,670 shares during the period. Prudential Financial Inc. owned about 0.53% of Genomic Health worth $5,992,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Dubuque Bank & Trust Co. grew its position in Genomic Health by 8.4% during the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after acquiring an additional 379 shares during the last quarter. SG Americas Securities LLC grew its position in Genomic Health by 37.8% during the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after acquiring an additional 1,679 shares during the last quarter. Legal & General Group Plc grew its position in Genomic Health by 48.7% during the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after acquiring an additional 2,038 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Genomic Health during the 1st quarter worth approximately $218,000. Finally, Envestnet Asset Management Inc. grew its position in Genomic Health by 13.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock worth $259,000 after acquiring an additional 993 shares during the last quarter. 88.90% of the stock is owned by hedge funds and other institutional investors.

Genomic Health, Inc. (GHDX) opened at 31.27 on Monday. The firm’s market cap is $1.08 billion. The stock has a 50 day moving average price of $30.90 and a 200-day moving average price of $31.60. Genomic Health, Inc. has a 1-year low of $26.37 and a 1-year high of $33.97.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period in the prior year, the firm earned ($0.18) EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Equities research analysts forecast that Genomic Health, Inc. will post ($0.01) EPS for the current year.

A number of equities research analysts recently commented on GHDX shares. Cowen and Company restated a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research report on Friday, September 1st. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Monday, June 12th. Piper Jaffray Companies restated a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research report on Thursday, August 3rd. Finally, BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $32.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/18/prudential-financial-inc-sells-11670-shares-of-genomic-health-inc-ghdx.html.

In other news, insider Phillip G. Febbo sold 3,174 shares of the company’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total transaction of $106,551.18. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $33.27, for a total transaction of $166,350.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,642 shares of company stock worth $1,354,431. 46.20% of the stock is owned by company insiders.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.